A61K 48/0033
The non-active part being non-polymeric
Official title: {the non-active part being non-polymeric}
A61K48/0033 (The non-active part being non-polymeric) appears on 277 US grants and 790 published applications in this corpus.
Search patents in A61K- Granted patents
- 277
- Published applications
- 790
- Assignees
- 337
- Inventors
- 1,566
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 0 | 4 |
| 2009 | 0 | 2 |
| 2010 | 0 | 6 |
| 2011 | 1 | 4 |
| 2012 | 2 | 7 |
| 2013 | 3 | 27 |
| 2014 | 8 | 41 |
| 2015 | 22 | 24 |
| 2016 | 19 | 30 |
| 2017 | 17 | 26 |
| 2018 | 19 | 45 |
| 2019 | 26 | 38 |
| 2020 | 23 | 33 |
| 2021 | 13 | 30 |
| 2022 | 12 | 48 |
| 2023 | 25 | 45 |
| 2024 | 18 | 132 |
| 2025 | 42 | 114 |
| 2026 | 27 | 126 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cationic lipid having disulfide bond, lipid membrane structure including same, nucleic acid introduction agent and pharmaceutical composition containing any one of same, method for introducing nucleic acid into cell or target cell, and method for producing cellular pharmaceutical29 Sep 2026US 12,746,202 B2National University Corporation Chiba University
- Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof22 Sep 2026US 12,741,930 B2Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Lipids and compositions thereof15 Sep 2026US 12,734,249 B2Generation Bio Co.
- Processes of preparing mRNA-loaded lipid nanoparticles15 Sep 2026US 12,734,253 B2Translate Bio, Inc.
- Compositions and methods for delivery of RNA1 Sep 2026US 12,721,818 B2Rejuvenation Technologies, Inc.
- Methods and materials for treating cancer8 Oct 2026US 2026/0306630 A1Mayo Foundation for Medical Education and Research
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies8 Oct 2026US 2026/0306664 A1AbbVie Inc.
Most cited
By later US patents
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides189US 8,754,062 B2Moderna Therapeutics, Inc. · 2014